Allergan, in Shift From Buying Spree, Considers a Spin-Off. by MICHAEL J. de la MERCED

By MICHAEL J. de la MERCED

The drugmaker had built itself into a $124 billion powerhouse in large part through repeated deals, for companies like Forest Laboratories.

Published: July 25, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1IjU6fU

from WordPress http://ift.tt/1IjUr25
via Hadi Aboukhater